StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock analysis

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

StockData Score

Prices as of Nov 17, 2026How the score works

Value0Growth0Performance0Health6Dividend0

Weak6 of 30 checks passed

Polaryx Therapeutics passes 6 of the 30 checks behind our score; 21 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
0/6
Financial health
6/6
Dividend
0/6

What stands out

  • No debt

    Polaryx Therapeutics has no borrowings on its latest balance sheet.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

  • Low bankruptcy risk

    The Altman Z-score is 28.68; above 3 is the safe zone and below 1.8 the distress zone.

What to watch

  • P/B above the industry

    Polaryx Therapeutics's price-to-book of 10.48 is above the Drugs median of 2.15.

  • Return on equity below the industry

    Polaryx Therapeutics's return on equity of -142% is below the Drugs median of -59.0%.

  • No dividend

    Polaryx Therapeutics has not paid a dividend in the last twelve months.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Polaryx Therapeutics's price-to-book of 10.48 is above the Drugs median of 2.15.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6
  • Revenue growth over 3 years

    Needs three years of positive revenue.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growth against the industry

    Needs revenue for this year and last.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance0/6
  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Polaryx Therapeutics's return on equity of -142% is below the Drugs median of -59.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin against its history

    Needs five years of revenue and net income.

  • Net margin against the industry

    Needs revenue and net income.

Financial health6/6
  • No debt

    Polaryx Therapeutics has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 8.62 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 28.68; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Polaryx Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

We don't publish a fair value for Polaryx Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$48.67K
Value traded per 1% price move
$16.26K

Downside

High risk

Typical loss in a bad month
69.3%
Volatility (annualized)
187%
Sharpe ratio, 1 year
-0.55
Beta to the S&P 500 (5Y)
–

Margins need revenue and profit figures

This company does not report the lines needed to calculate margins.

See a number that looks wrong?